Evidence map›Paper›PMID 38643450›Full record

Trial reportNaunyn-Schmiedeberg's archives of pharmacology2024

Pharmacokinetics and safety of a new generic lurasidone: a phase I bioequivalence study in healthy Chinese subjects.

Zhengzhi Liu, Jinling Xue, Qiaohuan Deng, Yanli Wang, Lixiu Zhang, Lang Liu, Nan Xiao, Tianying Chang, Yingzi Cui, Yang Cheng and 9 more

Abstract readClinical Trial, Phase IEquivalence TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Zhengzhi Liu *Phase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Jinling Xue *Clinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Qiaohuan DengPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Yanli WangPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Lixiu ZhangLung Disease Center, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Lang LiuThe Clinical Trial Quality Control Center, Ansiterui Medical Technology Consulting Co., Ltd., Changchun, China.
Nan XiaoClinical Research Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China.
Tianying ChangPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Yingzi CuiPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Yang ChengPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Guangwen LiuPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Wanhua WangPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Yannan ZhouPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Wei YangPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Xinyao QuPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Jiahui ChenPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.
Yicheng ZhaoCenter for Pathogen Biology and Infectious Diseases, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, The First Hospital of Jilin University, Changchun, China.
Zeyu WangNortheast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, China. zeyu781022@163.com.
Haimiao YangPhase I Clinical Trial Laboratory, Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China. haimiaoyang@outlook.com.
The Affiliated Hospital to Changchun University of Chinese Medicine · CNChangchun University of Chinese Medicine · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Latuda

Indexed as

Antipsychotic AgentsDrugs, GenericLurasidone HydrochlorideTherapeutic EquivalencyAdultArea Under CurveCross-Over StudiesEast Asian PeopleFemaleHealthy VolunteersHumansMaleYoung AdultAntipsychotic AgentsDrugs, GenericLurasidone HydrochlorideAntipsychoticBioequivalenceLurasidonePharmacokineticsTolerability

Identifiers

PMID38643450
OpenAlexW4394987834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.